Literature DB >> 18606225

Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

T Shantha Raju1.   

Abstract

IgG molecules contain glycans in the CH2 domain of the Fc fragment (N-glycosylation) which are highly heterogeneous, because of the presence of different terminal sugars. The heterogeneity of Fc glycans varies with species and expression system. Fc glycans influence the binding of IgG to Fc receptors and C1q, and are therefore important for IgG effector functions. Specifically, terminal sugars such as sialic acids, core fucose, bisecting N-acetylglucosamine, and mannose residues affect the binding of IgG to the FcgammaRIIIa receptor and thereby influence ADCC activity. By contrast, terminal galactose residues affect antibody binding to C1q and thereby modulate CDC activity. Structural studies indicate that the presence or absence of specific terminal sugars may affect hydrophilic and hydrophobic interactions between sugar residues and amino acid residues in the Fc fragment, which in turn may impact antibody effector functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606225     DOI: 10.1016/j.coi.2008.06.007

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  170 in total

1.  Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.

Authors:  Ralf Kircheis; Nicole Halanek; Iris Koller; Wolfgang Jost; Manfred Schuster; Gilbert Gorr; Klaus Hajszan; Andreas Nechansky
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

3.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 4.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 5.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

6.  EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.

Authors:  Stéphane Olivier; Marine Jacoby; Cédric Brillon; Sylvana Bouletreau; Thomas Mollet; Olivier Nerriere; Audrey Angel; Sévérine Danet; Boussad Souttou; Fabienne Guehenneux; Laurent Gauthier; Mathilde Berthomé; Henri Vié; Nicola Beltraminelli; Majid Mehtali
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

7.  Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.

Authors:  Denise Dorvignit; Julio L Palacios; Maylin Merino; Tays Hernández; Katya Sosa; Angel Casaco; Alejandro López-Requena; Cristina Mateo de Acosta
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 8.  Modulation of autoimmune rheumatic diseases by oestrogen and progesterone.

Authors:  Grant C Hughes; Divaker Choubey
Journal:  Nat Rev Rheumatol       Date:  2014-08-26       Impact factor: 20.543

Review 9.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

10.  A Functional Role for Antibodies in Tuberculosis.

Authors:  Lenette L Lu; Amy W Chung; Tracy R Rosebrock; Musie Ghebremichael; Wen Han Yu; Patricia S Grace; Matthew K Schoen; Fikadu Tafesse; Constance Martin; Vivian Leung; Alison E Mahan; Magdalena Sips; Manu P Kumar; Jacquelynne Tedesco; Hannah Robinson; Elizabeth Tkachenko; Monia Draghi; Katherine J Freedberg; Hendrik Streeck; Todd J Suscovich; Douglas A Lauffenburger; Blanca I Restrepo; Cheryl Day; Sarah M Fortune; Galit Alter
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.